Kadmon Holdings (Kadmon Holdings) EPS (Basic) : $-0.72 (TTM As of Sep. 2021)

View and export this data going back to 2016. Start your Free Trial

What is Kadmon Holdings EPS (Basic)?

Kadmon Holdings's basic earnings per share (Basic EPS) for the three months ended in Sep. 2021 was $-0.20. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2021 was $-0.72.

Kadmon Holdings's EPS (Diluted) for the three months ended in Sep. 2021 was $-0.20. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2021 was $-0.72.

Kadmon Holdings's EPS without NRI for the three months ended in Sep. 2021 was $-0.20. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2021 was -0.72.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Kadmon Holdings EPS (Basic) Historical Data

The historical data trend for Kadmon Holdings's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kadmon Holdings EPS (Basic) Chart

Kadmon Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

EPS (Basic)

Get a 7-Day Free Trial

-9.74

-1.42

-0.58

-0.48

-0.67

Kadmon Holdings Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
EPS (Basic)	Get a 7-Day Free Trial															-0.15	-0.17	-0.17	-0.18	-0.20

Kadmon Holdings EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Kadmon Holdings's Basic EPS for the fiscal year that ended in Dec. 2020 is calculated as

Basic EPS (A: Dec. 2020 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-108.913	-	2.122)	/	166.240
	=	-0.67

Kadmon Holdings's Basic EPS for the quarter that ended in Sep. 2021 is calculated as

Basic EPS (Q: Sep. 2021 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-33.623	-	0.571)	/	173.444
	=	-0.20

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.72

Kadmon Holdings (NAS:KDMN) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Kadmon Holdings EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Kadmon Holdings's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Kadmon Holdings (Kadmon Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kadmon Holdings Inc (NAS:KDMN) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

450 East 29th Street, New York, NY, USA, 10016

Website

https://www.kadmon.com

Kadmon Holdings Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of small molecules and biologics with a focus on inflammatory and fibrotic diseases. Its pipeline products include Belumosudil (KD025) and KD033.

Executives

Harlan Waksal	director, officer: President, CEO	WAKSAL CONSULTING LLC, 7 NORTH WILLOW STREET, SUITE 6, MONTCLAIR NJ 07042
Nancy Miller-rich	director	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001
Cynthia Schwalm	director	C/O G1 THERAPEUTICS, 700 PARK OFFICES DR, SUITE 200, P.O. BOX 110341, RESEARCH TRIANGLE PARK NC 27709
Arthur S Kirsch	director	7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
David E Cohen	director	3160 PORTER DRIVE, PALO ALTO CA 94304
Eugene Bauer	director	C/O KADMON HOLDINGS, LLC 450 E 29TH STREET NEW YORK NY 10016
Tasos Konidaris	director	103 JFK PARKWAY, SHORT HILLS NJ 07078
John L Ryan	officer: Executive Vice President, CMO	C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Steven Meehan	officer: EVP, Chief Financial Officer	450 E. 29TH STREET NEW YORK NY 10016
Kyle Carver	officer: Principal Accounting Officer, Controller	450 EAST 29TH STREET NEW YORK NY 10016
Gregory S. Moss	officer: EVP, General Counsel, Chief Compliance Officer	450 EAST 29TH STREET, 16TH FLOOR, NEW YORK NY 10016
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	other: Former 10% owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Steven N. Gordon	officer: Exec VP, GC, Chief Admin, Comp	C/O KADMON HOLDINGS, LLC 450 E 29TH STREET NEW YORK NY 10016